{
  "study_id": "METLung",
  "study_title": "Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung",
  "table_name": "Table 1",
  "table_title": "Baseline Characteristics of the ITT Population",
  "description": "Baseline demographic and clinical characteristics of the Intent-to-Treat (ITT) population for the METLung study.",
  "footnotes": [
    "*Stratification factor"
  ],
  "groups": [
    {
      "name": "Onartuzumab + Erlotinib",
      "n": 250,
      "type": "intervention"
    },
    {
      "name": "Placebo + Erlotinib",
      "n": 249,
      "type": "control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Median age, years",
      "standardized_name": "Age",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "numeric_single",
          "value": 62.0,
          "raw_string": "62"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "numeric_single",
          "value": 63.0,
          "raw_string": "63"
        }
      ]
    },
    {
      "original_label": "Sex",
      "standardized_name": "Sex",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "header",
          "raw_string": "Sex"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "header",
          "raw_string": "Sex"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex",
      "category": "Male",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 56.0,
          "raw_string": "139 (56)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 56.0,
          "raw_string": "139 (56)"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex",
      "category": "Female",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 44.0,
          "raw_string": "111 (44)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 110.0,
          "percentage": 44.0,
          "raw_string": "110 (44)"
        }
      ]
    },
    {
      "original_label": "ECOG PS",
      "standardized_name": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "header",
          "raw_string": "ECOG PS"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "header",
          "raw_string": "ECOG PS"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "0",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 37.0,
          "raw_string": "93 (37)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 31.0,
          "raw_string": "78 (31)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 153.0,
          "percentage": 61.0,
          "raw_string": "153 (61)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 169.0,
          "percentage": 68.0,
          "raw_string": "169 (68)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status",
      "category": "2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.0,
          "raw_string": "4 (2)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1 (0.5)"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "ECOG Performance Status",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1 (0.5)"
        }
      ]
    },
    {
      "original_label": "Asian race",
      "standardized_name": "Race",
      "category": "Asian",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 14.0,
          "raw_string": "35 (14)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 15.0,
          "raw_string": "37 (15)"
        }
      ]
    },
    {
      "original_label": "Histology*",
      "standardized_name": "Histology",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "header",
          "raw_string": "Histology*"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "header",
          "raw_string": "Histology*"
        }
      ]
    },
    {
      "original_label": "Nonsquamous",
      "standardized_name": "Histology",
      "category": "Nonsquamous",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 210.0,
          "percentage": 84.0,
          "raw_string": "210 (84)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 218.0,
          "percentage": 88.0,
          "raw_string": "218 (88)"
        }
      ]
    },
    {
      "original_label": "Squamous",
      "standardized_name": "Histology",
      "category": "Squamous",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 40.0,
          "percentage": 16.0,
          "raw_string": "40 (16)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 12.0,
          "raw_string": "31 (12)"
        }
      ]
    },
    {
      "original_label": "Prior lines of therapy*",
      "standardized_name": "Prior lines of therapy",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "header",
          "raw_string": "Prior lines of therapy*"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "header",
          "raw_string": "Prior lines of therapy*"
        }
      ]
    },
    {
      "original_label": "Two",
      "standardized_name": "Prior lines of therapy",
      "category": "Two",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior lines of therapy*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 161.0,
          "percentage": 64.0,
          "raw_string": "161 (64)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 157.0,
          "percentage": 63.0,
          "raw_string": "157 (63)"
        }
      ]
    },
    {
      "original_label": "Three",
      "standardized_name": "Prior lines of therapy",
      "category": "Three",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior lines of therapy*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 89.0,
          "percentage": 36.0,
          "raw_string": "89 (36)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 92.0,
          "percentage": 37.0,
          "raw_string": "92 (37)"
        }
      ]
    },
    {
      "original_label": "EGFR mutation positive*",
      "standardized_name": "EGFR mutation status",
      "category": "Positive",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 11.2,
          "raw_string": "28 (11.2)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 11.6,
          "raw_string": "29 (11.6)"
        }
      ]
    },
    {
      "original_label": "MET IHC*",
      "standardized_name": "MET Immunohistochemistry Score",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "header",
          "raw_string": "MET IHC*"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "header",
          "raw_string": "MET IHC*"
        }
      ]
    },
    {
      "original_label": "2+",
      "standardized_name": "MET Immunohistochemistry Score",
      "category": "2+",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "MET IHC*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 198.0,
          "percentage": 79.0,
          "raw_string": "198 (79)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 195.0,
          "percentage": 78.0,
          "raw_string": "195 (78)"
        }
      ]
    },
    {
      "original_label": "3+",
      "standardized_name": "MET Immunohistochemistry Score",
      "category": "3+",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "MET IHC*",
      "group_data": [
        {
          "group_name": "Onartuzumab + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 52.0,
          "percentage": 21.0,
          "raw_string": "52 (21)"
        },
        {
          "group_name": "Placebo + Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 22.0,
          "raw_string": "54 (22)"
        }
      ]
    }
  ]
}